Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
N. A. Avxentyev [verfasserIn] M. Yu. Frolov [verfasserIn] Yu. V. Makarova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Onkourologiâ - ABV-press, 2015, 15(2019), 2, Seite 86-99 |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2019 ; number:2 ; pages:86-99 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.17650/1726-9776-2019-15-2-86-99 |
|---|
| Katalog-ID: |
DOAJ030819938 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030819938 | ||
| 003 | DE-627 | ||
| 005 | 20230226194509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2019 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/1726-9776-2019-15-2-86-99 |2 doi | |
| 035 | |a (DE-627)DOAJ030819938 | ||
| 035 | |a (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a N. A. Avxentyev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. | ||
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a enzalutamide | |
| 650 | 4 | |a abiraterone | |
| 650 | 4 | |a pharmacoeconomic evaluation | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a M. Yu. Frolov |e verfasserin |4 aut | |
| 700 | 0 | |a Yu. V. Makarova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Onkourologiâ |d ABV-press, 2015 |g 15(2019), 2, Seite 86-99 |w (DE-627)1736705067 |x 17269776 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2019 |g number:2 |g pages:86-99 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/1726-9776-2019-15-2-86-99 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb |z kostenfrei |
| 856 | 4 | 0 | |u https://oncourology.abvpress.ru/oncur/article/view/958 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1726-9776 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1996-1812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2019 |e 2 |h 86-99 | ||
| author_variant |
n a a naa m y f myf y v m yvm |
|---|---|
| matchkey_str |
article:17269776:2019----::hraocnmcsetouignauaienaiaeoeotetetfhmteayavptetwtmts |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.17650/1726-9776-2019-15-2-86-99 doi (DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb DE-627 ger DE-627 rakwb rus N. A. Avxentyev verfasserin aut Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R M. Yu. Frolov verfasserin aut Yu. V. Makarova verfasserin aut In Onkourologiâ ABV-press, 2015 15(2019), 2, Seite 86-99 (DE-627)1736705067 17269776 nnns volume:15 year:2019 number:2 pages:86-99 https://doi.org/10.17650/1726-9776-2019-15-2-86-99 kostenfrei https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb kostenfrei https://oncourology.abvpress.ru/oncur/article/view/958 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2019 2 86-99 |
| spelling |
10.17650/1726-9776-2019-15-2-86-99 doi (DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb DE-627 ger DE-627 rakwb rus N. A. Avxentyev verfasserin aut Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R M. Yu. Frolov verfasserin aut Yu. V. Makarova verfasserin aut In Onkourologiâ ABV-press, 2015 15(2019), 2, Seite 86-99 (DE-627)1736705067 17269776 nnns volume:15 year:2019 number:2 pages:86-99 https://doi.org/10.17650/1726-9776-2019-15-2-86-99 kostenfrei https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb kostenfrei https://oncourology.abvpress.ru/oncur/article/view/958 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2019 2 86-99 |
| allfields_unstemmed |
10.17650/1726-9776-2019-15-2-86-99 doi (DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb DE-627 ger DE-627 rakwb rus N. A. Avxentyev verfasserin aut Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R M. Yu. Frolov verfasserin aut Yu. V. Makarova verfasserin aut In Onkourologiâ ABV-press, 2015 15(2019), 2, Seite 86-99 (DE-627)1736705067 17269776 nnns volume:15 year:2019 number:2 pages:86-99 https://doi.org/10.17650/1726-9776-2019-15-2-86-99 kostenfrei https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb kostenfrei https://oncourology.abvpress.ru/oncur/article/view/958 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2019 2 86-99 |
| allfieldsGer |
10.17650/1726-9776-2019-15-2-86-99 doi (DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb DE-627 ger DE-627 rakwb rus N. A. Avxentyev verfasserin aut Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R M. Yu. Frolov verfasserin aut Yu. V. Makarova verfasserin aut In Onkourologiâ ABV-press, 2015 15(2019), 2, Seite 86-99 (DE-627)1736705067 17269776 nnns volume:15 year:2019 number:2 pages:86-99 https://doi.org/10.17650/1726-9776-2019-15-2-86-99 kostenfrei https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb kostenfrei https://oncourology.abvpress.ru/oncur/article/view/958 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2019 2 86-99 |
| allfieldsSound |
10.17650/1726-9776-2019-15-2-86-99 doi (DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb DE-627 ger DE-627 rakwb rus N. A. Avxentyev verfasserin aut Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R M. Yu. Frolov verfasserin aut Yu. V. Makarova verfasserin aut In Onkourologiâ ABV-press, 2015 15(2019), 2, Seite 86-99 (DE-627)1736705067 17269776 nnns volume:15 year:2019 number:2 pages:86-99 https://doi.org/10.17650/1726-9776-2019-15-2-86-99 kostenfrei https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb kostenfrei https://oncourology.abvpress.ru/oncur/article/view/958 kostenfrei https://doaj.org/toc/1726-9776 Journal toc kostenfrei https://doaj.org/toc/1996-1812 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2019 2 86-99 |
| language |
Russian |
| source |
In Onkourologiâ 15(2019), 2, Seite 86-99 volume:15 year:2019 number:2 pages:86-99 |
| sourceStr |
In Onkourologiâ 15(2019), 2, Seite 86-99 volume:15 year:2019 number:2 pages:86-99 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Onkourologiâ |
| authorswithroles_txt_mv |
N. A. Avxentyev @@aut@@ M. Yu. Frolov @@aut@@ Yu. V. Makarova @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
1736705067 |
| id |
DOAJ030819938 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ030819938</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230226194509.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/1726-9776-2019-15-2-86-99</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030819938</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. A. Avxentyev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enzalutamide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abiraterone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacoeconomic evaluation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Makarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">15(2019), 2, Seite 86-99</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:86-99</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/1726-9776-2019-15-2-86-99</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://oncourology.abvpress.ru/oncur/article/view/958</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">86-99</subfield></datafield></record></collection>
|
| author |
N. A. Avxentyev |
| spellingShingle |
N. A. Avxentyev misc prostate cancer misc enzalutamide misc abiraterone misc pharmacoeconomic evaluation misc Medicine misc R Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| authorStr |
N. A. Avxentyev |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1736705067 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
17269776 |
| topic_title |
Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer prostate cancer enzalutamide abiraterone pharmacoeconomic evaluation |
| topic |
misc prostate cancer misc enzalutamide misc abiraterone misc pharmacoeconomic evaluation misc Medicine misc R |
| topic_unstemmed |
misc prostate cancer misc enzalutamide misc abiraterone misc pharmacoeconomic evaluation misc Medicine misc R |
| topic_browse |
misc prostate cancer misc enzalutamide misc abiraterone misc pharmacoeconomic evaluation misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Onkourologiâ |
| hierarchy_parent_id |
1736705067 |
| hierarchy_top_title |
Onkourologiâ |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1736705067 |
| title |
Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| ctrlnum |
(DE-627)DOAJ030819938 (DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb |
| title_full |
Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| author_sort |
N. A. Avxentyev |
| journal |
Onkourologiâ |
| journalStr |
Onkourologiâ |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
86 |
| author_browse |
N. A. Avxentyev M. Yu. Frolov Yu. V. Makarova |
| container_volume |
15 |
| format_se |
Elektronische Aufsätze |
| author-letter |
N. A. Avxentyev |
| doi_str_mv |
10.17650/1726-9776-2019-15-2-86-99 |
| author2-role |
verfasserin |
| title_sort |
pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| title_auth |
Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| abstract |
Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. |
| abstractGer |
Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. |
| abstract_unstemmed |
Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
2 |
| title_short |
Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer |
| url |
https://doi.org/10.17650/1726-9776-2019-15-2-86-99 https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb https://oncourology.abvpress.ru/oncur/article/view/958 https://doaj.org/toc/1726-9776 https://doaj.org/toc/1996-1812 |
| remote_bool |
true |
| author2 |
M. Yu. Frolov Yu. V. Makarova |
| author2Str |
M. Yu. Frolov Yu. V. Makarova |
| ppnlink |
1736705067 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17650/1726-9776-2019-15-2-86-99 |
| up_date |
2024-07-03T17:09:02.854Z |
| _version_ |
1803578552204918784 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ030819938</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230226194509.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/1726-9776-2019-15-2-86-99</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030819938</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6c31cbf4656340afac8e72b9479dacbb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">N. A. Avxentyev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Enzalutamide and abiraterone are hormonal antineoplastic drugs used for treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs were proved to be effective in randomized controlled trials.Objective. Pharmacoeconomic analysis of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with mCRPC from the perspective of Russian healthcare system in 2019.Materials and methods. We proposed a Markov model of mCRPC progression on three treatment options: enzalutamide, abiraterone or active monitoring with no antineoplastic treatment in the 1st line setting. The model was based on indirect treatment comparison of considered drugs. Modelling period was 5 years. The model was used for calculating per patient medical costs, and further cost–effectiveness, cost–utility and budget impact analysis.Results. Monthly medication costs of enzalutamide were 183 551 rubles, which were 23 766 rubles (11.5 %) less than for abiraterone (207 224 rubles). 5-year total medical costs for enzalutamide were 5633 thousand rubles per patient, that were 67 499 rubles (1.2 %) less than for abiraterone. Incremental cost/effectiveness ratio for enzalutamide vs active monitoring was 533 thousand rubles per one life-month gained, compared to 623 thousand rubles per one life-month gained for abiraterone. If 7328 mCRPC chemotherapy-naive patients receive enzalutamide, Russian government healthcare spending will be 495 million rubles (1.2 %) less, compared to abiraterone.Conclusion. With comparable costs enzalutamide is a cost-effective treatment option of chemotherapy-naive mCRPC patients, compared to abiraterone, in Russia.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enzalutamide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">abiraterone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pharmacoeconomic evaluation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu. V. Makarova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Onkourologiâ</subfield><subfield code="d">ABV-press, 2015</subfield><subfield code="g">15(2019), 2, Seite 86-99</subfield><subfield code="w">(DE-627)1736705067</subfield><subfield code="x">17269776</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:86-99</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/1726-9776-2019-15-2-86-99</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6c31cbf4656340afac8e72b9479dacbb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://oncourology.abvpress.ru/oncur/article/view/958</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1726-9776</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1996-1812</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">86-99</subfield></datafield></record></collection>
|
| score |
7.402135 |